Sterling Investment Advisors Ltd. Purchases 18,581 Shares of Pfizer Inc. $PFE

Sterling Investment Advisors Ltd. lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 14.9% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 143,333 shares of the biopharmaceutical company’s stock after buying an additional 18,581 shares during the quarter. Sterling Investment Advisors Ltd.’s holdings in Pfizer were worth $3,451,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Angeles Wealth Management LLC increased its stake in Pfizer by 2.2% during the 2nd quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company’s stock valued at $410,000 after purchasing an additional 358 shares in the last quarter. Manchester Financial Inc. lifted its holdings in Pfizer by 2.9% during the second quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company’s stock worth $317,000 after acquiring an additional 365 shares during the period. Vermillion Wealth Management Inc. raised its stake in shares of Pfizer by 19.4% during the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 382 shares during the period. Eagle Capital Management LLC boosted its stake in Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock valued at $3,554,000 after acquiring an additional 390 shares during the last quarter. Finally, Delta Financial Advisors LLC lifted its stake in Pfizer by 1.6% in the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after purchasing an additional 398 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

NYSE:PFE opened at $27.78 on Wednesday. Pfizer Inc. has a twelve month low of $23.58 and a twelve month high of $29.21. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The firm’s fifty day simple moving average is $26.13 and its 200 day simple moving average is $26.35. The stock has a market cap of $158.34 billion, a P/E ratio of 36.55, a price-to-earnings-growth ratio of 1.91 and a beta of 0.34.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th were given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.2%. The ex-dividend date of this dividend was Friday, July 24th. Pfizer’s payout ratio is presently 226.32%.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent research reports. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and dropped their price target for the company from $32.00 to $28.00 in a research note on Monday, July 6th. Bank of America reduced their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. UBS Group reaffirmed a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research note on Wednesday, May 27th. Finally, Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $28.28.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s recent quarterly results exceeded expectations, with adjusted earnings per share of $0.77 versus a $0.68 consensus estimate and revenue of $15.03 billion, above the $14.40 billion forecast. The earnings beat helped revive the shares during August and supports confidence in the company’s ability to execute despite post-COVID revenue challenges. Why Pfizer Stock Was so Healthy in August
• Positive Sentiment: Pfizer’s roughly 6% dividend yield remains a major attraction for income-focused investors. Some analysts also see upside from a pipeline that is beginning to gain investor attention, with one commentary assigning a 12-month price target of $32.72 based on dividend support and potential pipeline progress. Forget the Dividend: This Could Be the Real Reason to Buy Pfizer Stock Now
• Neutral Sentiment: Chief Executive Officer Albert Bourla is scheduled to speak at the Morgan Stanley Global Healthcare Conference on September 14. Investors may look for updates on the pipeline, capital allocation and the company’s growth strategy. Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
• Negative Sentiment: Pfizer’s high yield is not viewed as the strongest dividend-growth opportunity. Comparisons with AbbVie argue that Pfizer offers income today but may have less attractive long-term dividend growth, potentially limiting demand from total-return investors. Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now
• Negative Sentiment: Novartis India’s $132 million acquisition of Pfizer brands indicates continued portfolio reshaping, but the divestiture also removes established products and revenue from Pfizer’s business. Meanwhile, Lilly’s expanding neuroscience pipeline highlights intensifying competition for future growth in innovative medicines. Novartis India Acquires Pfizer Brands

Pfizer Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer’s products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.